Bristol Myers Squibb Promotes Health Equity with 100 Percent of Marketed Products Now Supported by Access Plans

Rhea-AI Summary

Bristol Myers Squibb (BMY) has announced that 100% of its marketed products are now supported by access plans, as part of its 10-year ASPIRE strategy to promote health equity and increase access to medicines in low- and middle-income countries (LMICs). The company aims to reach over 208,000 patients in LMICs by 2033. BMS is collaborating with the Access to Oncology Medicines (ATOM) Coalition to make Opdivo (nivolumab) available in select countries including Pakistan, Rwanda, and Zambia. This initiative is part of BMS's broader commitment to health equity and its Environmental, Social and Governance (ESG) strategy, focusing on reducing quality-of-care gaps and strengthening health systems globally.

Positive

• 100% of marketed products now supported by access plans
• Goal to reach over 208,000 patients in LMICs by 2033
• Collaboration with ATOM Coalition to expand access to Opdivo in select countries
• Development of tailored strategies to increase affordability and availability of medicines in LMICs

Negative

• None.

News Market Reaction – BMY

+1.37%

1 alert

+1.37% News Effect

On the day this news was published, BMY gained 1.37%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

10-year strategy to advance access to our innovative treatments and help patients in low- and middle-income countries (LMICs)

NORTHAMPTON, MA / ACCESSWIRE / July 25, 2024 / At BMS, our vision to transform patients' lives through science extends to all patients. That is why we have a long-standing commitment to promote health equity and help people in underserved communities access the care and medicines they need.

We built on this commitment with a 10-year strategy to help patients in LMICs (low- and middle-income countries) live healthier lives, called ASPIRE, which stands for Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity. ASPIRE will help us achieve our goal to reach more than 208,000 patients in LMICs by 2033. The effort reflects our unwavering focus on operating responsibly and sustainably.

As part of ASPIRE, BMS is developing tailored strategies to increase affordability and availability of its medicines in LMICs. Our work to help ensure patients who need our potentially life-saving medicines can access them begins by ensuring that 100 percent of our marketed products are supported by access plans.

Today, we have defined access pathways for every country in which our medicines may be available to patients and have achieved our goal of 100 percent of our marketed products be supported by access plans.

The imbalance in healthcare access is just one of the systemic barriers faced by the world's most vulnerable populations, where worse health outcomes and lack of economic opportunities keep individuals and entire communities from achieving their full potential.

BMS is leading the way for access to immuno-oncology therapies in LMICs by collaborating with the Access to Oncology Medicines (ATOM) Coalition. BMS joined the ATOM Coalition as a founding supporter at its launch in 2022. Working with the ATOM Coalition and their partners, BMS will make Opdivo™ (nivolumab) available via a safe, scalable and sustainable access model in select countries including Pakistan, Rwanda and Zambia while working to develop an integrated pathway that can expand access in multiple LMICs by 2026.

By investing in solutions that reduce quality-of-care gaps and strengthen health systems, BMS will help drive equitable access to innovative medicines to patients around the world, regardless of where patients live. Enabling timely access to innovative medicines in LMICs is part of BMS' commitment to health equity globally and our Environmental, Social and Governance (ESG) strategy.

To learn more, read our press release.

View additional multimedia and more ESG storytelling from Bristol Myers Squibb Company on 3blmedia.com.

Contact Info:
Spokesperson: Bristol Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com

SOURCE: Bristol Myers Squibb Company

View the original press release on accesswire.com

FAQ

What is Bristol Myers Squibb's (BMY) ASPIRE strategy?

ASPIRE is BMS's 10-year strategy to help patients in low- and middle-income countries (LMICs) access care and medicines. It stands for Accessibility, Sustainability, Patient-centric, Impact, Responsibility and Equity, aiming to reach over 208,000 patients in LMICs by 2033.

How is Bristol Myers Squibb (BMY) improving access to its medicines in LMICs?

BMS has developed access plans for 100% of its marketed products, defined access pathways for every country where its medicines may be available, and is collaborating with the ATOM Coalition to make Opdivo available in select countries like Pakistan, Rwanda, and Zambia.

What is Bristol Myers Squibb's (BMY) goal for patient reach in LMICs by 2033?

Bristol Myers Squibb aims to reach more than 208,000 patients in low- and middle-income countries (LMICs) by 2033 through its ASPIRE strategy.

Which Bristol Myers Squibb (BMY) product is being made available through the ATOM Coalition?

Bristol Myers Squibb is making Opdivo (nivolumab), an immuno-oncology therapy, available through the Access to Oncology Medicines (ATOM) Coalition in select countries including Pakistan, Rwanda, and Zambia.